Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase II trial of selinexor + VRd induction therapy for patients with NDMM and EMD finds ORR 89.7% (sCR 58.6%, CR 3.4%, VGPR 10.3%, PR 17.2%), imaging EMD regression in 89.7%; 12-mo. PFS and OS rates 87.9% and 96.3%, respectively.”
Title: Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial
Authors: Yuanyuan Jin, Xin Cheng, Xuezhong Zhang, Qinglin Shi, Yu Zhu, Jianyong Li, Lei Fan, Lijuan Chen
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
